{"generic":"Coagulation Factor VIIa","drugs":["Coagulation Factor VIIa","Novoseven","NovoSeven RT"],"mono":{"0":{"id":"928471-s-0","title":"Generic Names","mono":"Coagulation Factor VIIa"},"1":{"id":"928471-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928471-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acquired factor VIII deficiency disease - Bleeding:<\/b> 70 to 90 mcg\/kg slow IV bolus (over 2 to 5 minutes) every 2 to 3 hours until hemostasis<\/li><li><b>Acquired factor VIII deficiency disease - Postoperative hemorrhage; Prophylaxis:<\/b> 70 to 90 mcg\/kg slow IV bolus (over 2 to 5 minutes) immediately prior to surgery; repeat every 2 to 3 hours during surgery and until hemostasis achieved<\/li><li><b>Bleeding - Factor VII deficiency, Congenital:<\/b> 15 to 30 mcg\/kg IV bolus over 2 to 5 minutes, every 4 to 6 hours until hemostasis achieved; adjust dose and frequency as necessary<\/li><li><b>Bleeding - Glanzmann's thrombasthenia:<\/b> 90 mcg\/kg IV bolus every 2 to 6 hours; for severe bleeding, continue until hemostasis is achieved<\/li><li><b>Bleeding - Hemophilia, with inhibitors to Factor VIII or Factor IX:<\/b> initial; 90 mcg\/kg IV bolus over 2 to 5 minutes, then repeat every 2 hours until hemostasis is achieved or until treatment is judged to be inadequate; adjust dose and interval (35 to 120 mcg\/kg has been used successfully) based on severity of bleeding and degree of hemostasis achieved<\/li><li><b>Bleeding - Hemophilia, with inhibitors to Factor VIII or Factor IX:<\/b> post-hemostatic dosing; appropriate duration not studied; for severe bleeds, continue 90 mcg\/kg IV bolus every 3 to 6 hours to maintain hemostatic plug<\/li><li><b>Bleeding - Hemophilia, with inhibitors to Factor VIII or Factor IX:<\/b> at-home treatment, 90 mcg\/kg IV bolus followed by 15 to 16 mcg\/kg\/hr for 12 hours with a target trough blood factor VII level of 10 units\/mL, OR 160 to 180 mcg\/kg bolus followed by 30 mcg\/kg\/hr for 6 hours with a target trough blood factor VII level of 20 units\/mL<\/li><li><b>Factor VII deficiency, Congenital - Postoperative hemorrhage; Prophylaxis:<\/b> 15 to 30 mcg\/kg IV bolus over 2 to 5 minutes immediately prior to surgery, then repeat every 4 to 6 hours until hemostasis achieved; adjust dose and frequency as necessary<\/li><li><b>Glanzmann's thrombasthenia - Postoperative hemorrhage; Prophylaxis:<\/b> initial, 90 mcg\/kg IV BOLUS immediately prior to surgery; repeat every 2 hours for duration of procedure<\/li><li><b>Glanzmann's thrombasthenia - Postoperative hemorrhage; Prophylaxis:<\/b> postsurgical, 90 mcg\/kg IV BOLUS every 2 to 6 hours<\/li><li><b>Hemophilia, with inhibitors to Factor VIII or Factor IX - Postoperative hemorrhage; Prophylaxis:<\/b> initial: 90 mcg\/kg IV bolus over 2 to 5 minutes; administer immediately prior to intervention and repeat every 2 hours for duration of surgery<\/li><li><b>Hemophilia, with inhibitors to Factor VIII or Factor IX - Postoperative hemorrhage; Prophylaxis:<\/b> postsurgical, minor surgery: continue dosing every 2 hours for first 48 hours, then every 2 to 6 hours until healing has occurred<\/li><li><b>Hemophilia, with inhibitors to Factor VIII or Factor IX - Postoperative hemorrhage; Prophylaxis:<\/b> postsurgical, major surgery: continue dosing every 2 hours for 5 days, then every 4 hours until healing has occurred<\/li><\/ul>"},"1":{"id":"928471-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Acquired factor VIII deficiency disease - Bleeding:<\/b> (NovoSeven(R)) 70 to 90 mcg\/kg slow IV bolus (over 2 to 5 minutes) every 2 to 3 hours until hemostasis<\/li><li><b>Acquired factor VIII deficiency disease - Postoperative hemorrhage; Prophylaxis:<\/b> (NovoSeven(R)) 70 to 90 mcg\/kg slow IV bolus IV (over 2 to 5 minutes) immediately prior to surgery; repeat every 2 to 3 hours during surgery and until hemostasis<\/li><li><b>Bleeding - Factor VII deficiency, Congenital:<\/b> 15 to 30 mcg\/kg IV bolus over 2 to 5 minutes, every 4 to 6 hours until hemostasis achieved; adjust dose and frequency as necessary<\/li><li><b>Bleeding - Glanzmann's thrombasthenia:<\/b> 90 mcg\/kg IV bolus every 2 to 6 hours; for severe bleeding, continue until hemostasis is achieved<\/li><li><b>Bleeding - Hemophilia, with inhibitors to Factor VIII or Factor IX:<\/b> initial; 90 mcg\/kg IV bolus over 2 to 5 minutes, then repeat every 2 hours until hemostasis is achieved or until treatment is judged to be inadequate; adjust dose and interval (35 to 120 mcg\/kg has been used successfully) based on severity of bleeding and degree of hemostasis achieved<\/li><li><b>Bleeding - Hemophilia, with inhibitors to Factor VIII or Factor IX:<\/b> post-hemostatic dosing; appropriate duration not studied; for severe bleeds, continue 90 mcg\/kg IV bolus every 3 to 6 hours to maintain hemostatic plug<\/li><li><b>Factor VII deficiency, Congenital - Postoperative hemorrhage; Prophylaxis:<\/b> 15 to 30 mcg\/kg IV bolus over 2 to 5 minutes immediately prior to surgery, then repeat every 4 to 6 hours until hemostasis achieved; adjust dose and frequency as necessary<\/li><li><b>Glanzmann's thrombasthenia - Postoperative hemorrhage; Prophylaxis:<\/b> initial, 90 mcg\/kg IV BOLUS immediately prior to surgery; repeat every 2 hours for duration of procedure<\/li><li><b>Glanzmann's thrombasthenia - Postoperative hemorrhage; Prophylaxis:<\/b> postsurgical, 90 mcg\/kg IV BOLUS every 2 to 6 hours<\/li><li><b>Hemophilia, with inhibitors to Factor VIII or Factor IX - Postoperative hemorrhage; Prophylaxis:<\/b> initial: 90 mcg\/kg IV bolus over 2 to 5 minutes; administer immediately prior to intervention and repeat every 2 hours for duration of surgery<\/li><li><b>Hemophilia, with inhibitors to Factor VIII or Factor IX - Postoperative hemorrhage; Prophylaxis:<\/b> postsurgical, minor surgery: 90 mcg\/kg IV bolus every 2 hours for first 48 hours, then every 2 to 6 hours until healing has occurred<\/li><li><b>Hemophilia, with inhibitors to Factor VIII or Factor IX - Postoperative hemorrhage; Prophylaxis:<\/b> postsurgical, major surgery; 90 mcg\/kg IV bolus  every 2 hours for 5 days, then every 4 hours until healing has occurred<\/li><\/ul>"},"3":{"id":"928471-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acquired factor VIII deficiency disease - Bleeding<\/li><li>Acquired factor VIII deficiency disease - Postoperative hemorrhage; Prophylaxis<\/li><li>Bleeding - Factor VII deficiency, Congenital<\/li><li>Bleeding - Glanzmann's thrombasthenia<\/li><li>Bleeding - Hemophilia, with inhibitors to Factor VIII or Factor IX<\/li><li>Factor VII deficiency, Congenital - Postoperative hemorrhage; Prophylaxis<\/li><li>Glanzmann's thrombasthenia - Postoperative hemorrhage; Prophylaxis<\/li><li>Hemophilia, with inhibitors to Factor VIII or Factor IX - Postoperative hemorrhage; Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Drug action reversal, Anticoagulation<\/li><li>Postoperative hemorrhage, Cardiac Surgery<\/li><\/ul>"}}},"2":{"id":"928471-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Powder for Solution)<\/b><br\/>Serious arterial and venous thrombotic events are associated with the use of coagulation factor VIIa. Patients should be advised of the risks and know the signs and symptoms of thrombotic and thromboembolic events. Monitor for signs\/symptoms of thrombosis and of activation of the coagulation cascade.<br\/>"},"3":{"id":"928471-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928471-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"928471-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- serious arterial and venous thrombotic events, including a fatal event, have been reported and caution is advised in patients at increased risk of thromboembolic complications; monitoring recommended; dose reduction or discontinuation may be necessary<\/li><li>Cardiovascular:<\/li><li>-- advanced atherosclerotic disease increases risk of thrombotic events due to circulating tissue factor or predisposing coagulopathy; monitoring recommended; dose reduction or discontinuation may be necessary<\/li><li>-- history of coronary heart disease increases risk of thromboembolic complications; monitoring recommended; dose reduction or discontinuation may be necessary<\/li><li>Hematologic:<\/li><li>-- DIC or history of DIC increases risk of thrombotic events due to circulating tissue factor or predisposing coagulopathy; monitoring recommended; dose reduction or discontinuation may be necessary<\/li><li>Hepatic:<\/li><li>-- history of liver disease increases risk of thromboembolic complications; monitoring recommended; dose reduction or discontinuation may be necessary<\/li><li>Immunologic:<\/li><li>-- hypersensitivity reactions, including anaphylaxis, have been reported; administer only if clearly needed to patients with history of known hypersensitivity to recombinant coagulation factor VIIa, any of the product components, or to mouse, hamster, or bovine proteins; discontinue if symptoms occur, administer appropriate treatment, and weigh benefit and risks before restarting therapy<\/li><li>-- factor VII deficient patients may develop antibodies; monitoring recommended and analysis for antibodies may be necessary<\/li><li>Reproductive:<\/li><li>-- uncontrolled postpartum hemorrhage increases risk of thrombotic events due to circulating tissue factor or predisposing coagulopathy; monitoring recommended; dose reduction or discontinuation may be necessary<\/li><li>Other:<\/li><li>-- crush injury increases risk of thrombotic events due to circulating tissue factor or predisposing coagulopathy; monitoring recommended; dose reduction or discontinuation may be necessary<\/li><li>-- septicemia increases risk of thrombotic events due to circulating tissue factor or predisposing coagulopathy; monitoring recommended; dose reduction or discontinuation may be necessary<\/li><li>-- history of postoperative immobilization increases risk of thromboembolic complications; monitoring recommended; dose reduction or discontinuation may be necessary<\/li><li>-- elderly patients have an increased risk of thromboembolic complications; monitoring recommended; dose reduction or discontinuation may be necessary<\/li><li>-- neonates have an increased risk of thromboembolic complications; monitoring recommended; dose reduction or discontinuation may be necessary<\/li><li>Concomitant use:<\/li><li>-- activated or nonactivated prothrombin complex concentrates (aPCCs\/PCCs) increase risk of thrombotic events due to circulating tissue factor or predisposing coagulopathy; monitoring recommended; dose reduction or discontinuation may be necessary<\/li><\/ul>"},{"id":"928471-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B1 (AUS)<\/li><\/ul>"},{"id":"928471-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928471-s-4","title":"Drug Interactions","sub":{"1":{"id":"928471-s-4-14","title":"Major","mono":"<ul><li>Factor XIII (theoretical)<\/li><li>Prothrombin Complex (theoretical)<\/li><\/ul>"}}},"5":{"id":"928471-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension (2% or greater)<\/li><li><b>Other:<\/b>Fever (2% or more)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction, Supraventricular tachycardia (0.1%)<\/li><li><b>Hematologic:<\/b>Arterial thromboembolism, Deep venous thrombosis, Disseminated intravascular coagulation, Thrombophlebitis, Thrombosis (Acquired hemophilia, 4%; congenital hemophilia, 0.2%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Cerebral artery occlusion, Cerebral ischemia, Hydrocephalus<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><\/ul>"},"6":{"id":"928471-s-6","title":"Drug Name Info","sub":{"0":{"id":"928471-s-6-17","title":"US Trade Names","mono":"<ul><li>Novoseven<\/li><li>NovoSeven RT<\/li><\/ul>"},"2":{"id":"928471-s-6-19","title":"Class","mono":"Hemostatic<br\/>"},"3":{"id":"928471-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928471-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928471-s-7","title":"Mechanism Of Action","mono":" Factor VIIa is a vitamin K-dependent glycoprotein structurally similar to human plasma-derived factor VIIa. It promotes hemostasis by complexing with tissue factor and activating coagulation factors in the intrinsic pathway: factor X to factor Xa, and factor IX to factor IXa. Activated factor X (factor Xa), complexed with other factors, converts prothrombin to thrombin and fibrinogen to fibrin to form a hemostatic plug.<br\/>"},"8":{"id":"928471-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"928471-s-8-24","title":"Distribution","mono":"<ul><li>Vd, Adults with hemophilia A or B: 105  to 128 mL\/kg<\/li><li>Vd, adults with factor VII deficiency: 280 to 290 mL\/kg<\/li><li>Vd, pediatric patients with hemophilia A or B: 130  to 164 mL\/kg<\/li><\/ul>"},"3":{"id":"928471-s-8-26","title":"Excretion","mono":"<ul><li>Total body clearance, adults with hemophilia A or B: 30 mL\/hr\/kg  to 39  mL\/hr\/kg<\/li><li>Total body clearance, adults with factor VII deficiency: 70.8 to 79.1 mL\/hr\/kg<\/li><li>Total body clearance, pediatric patients with hemophilia A or B: 58 mL\/hr\/kg  to 67 mL\/kg\/hr<\/li><\/ul>"},"4":{"id":"928471-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Adults with hemophilia A or B: 2.3  to 3.1 hours<\/li><li>Adults with factor VII deficiency: 2.81 to 3.11 hours<\/li><li>Pediatric patients with hemophilia A or B: 1.32  to 2.6 hours<\/li><\/ul>"}}},"9":{"id":"928471-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>NovoSeven(R): use the following volumes of sterile water for injection to dilute, 2.2 mL in the 1.2-mg vial; 4.3 mL in the 2.4-mg vial; 8.5 mL in the 4.8-mg vial; the final concentration for each vial contains approximately 0.6 mg\/mL (600 mcg\/mL)<\/li><li>NovoSeven(R) RT: reconstitute ONLY with the histidine diluent provided<\/li><li>NovoSeven(R) RT: reconstitute with the following volumes of histidine diluent from the provided vial, 1.1 mL in the 1-mg vial; 2.1 mL in the 2-mg vial; 5.2 mL in the 5-mg vial; 8.1 mL in the 8-mg vial; the final concentration for each vial is approximately 1 mg\/mL (1000 mcg\/mL)<\/li><li>NovoSeven(R) RT: reconstitute with the following volumes of histidine diluent from the provided prefilled syringes of histidine diluent, 1 mL in the 1-mg vial; 2 mL  in the 2-mg vial; 5 mL in the 5-mg vial; 8 mL in the 8-mg vial; the final concentration for each vial is approximately 1 mg\/mL (1000 mcg\/mL)<\/li><li>inject diluent against side of vial; do not inject diluent directly on powder<\/li><li>gently swirl vial to dissolve powder<\/li><li>prefilled glass diluent syringes are incompatible with some need&le;ss connectors; requires withdrawing reconstituted product into a standard 10-mL syringe prior to administration<\/li><li>administer only by IV bolus, slowly over 2 to 5 minutes<\/li><li>administer solution within 3 hours after reconstitution<\/li><li>if line needs to be flushed before or after, use 0.9% sodium chloride injection<\/li><\/ul>"},"10":{"id":"928471-s-10","title":"Monitoring","mono":"<ul><li>prothrombin time and factor VII coagulant activity; prior to and following administration in factor VII deficient patients; evaluate for antibodies if expected levels are not reached, prothrombin time is not corrected, or bleeding is uncontrolled<\/li><li>hemostasis: to determine efficacy and treatment schedule<\/li><li>signs or symptoms of thrombosis or activation of the coagulation system<\/li><\/ul>"},"11":{"id":"928471-s-11","title":"How Supplied","mono":"<b>NovoSeven RT<\/b><br\/>Intravenous Powder for Solution: 1 MCG<br\/>"},"13":{"id":"928471-s-13","title":"Clinical Teaching","mono":"Instruct patient to report signs\/symptoms of bleeding or thrombosis.<br\/>"}}}